Ischemix Announces Positive Top Line Data from Phase 2 Clinical Trial of CMX-2043
“We believe that the Phase 2 safety and efficacy data for CMX-2043 are very promising. CMX-2043 represents a potential new approach to prevention of peri-operative ischemia-reperfusion injury, a field where previous drug candidates have not succeeded in clinical studies,” commented Duffy DuFresne, Chief Executive Officer of Ischemix.
About the Phase 2a Trial
The Phase 2a trial of CMX-2043 was a multi-center trial for the prevention of peri-operative ischemia-reperfusion injury in patients undergoing elective percutaneous coronary intervention at higher risk for peri-operative cardiac injury. This prospective, randomized, double-blind, placebo-controlled trial compared three intravenous dosing levels of CMX-2043. The primary endpoint of the study was safety assessment of CMX-2043 injection. Secondary outcomes evaluated the efficacy of CMX-2043 based on changes observed in biomarkers of cardiac injury, including CK-MB and Troponin T as well as continuous electrocardiographic monitoring.
About Ischemix
Ischemix is a privately-held drug discovery company with a portfolio of small molecule therapeutic compounds. The first of these compounds is targeted to reduce cell death and organ damage due to initial interruption and subsequent resumption of blood flow associated with cardiac surgeries and interventional procedures such as percutaneous coronary intervention ("PCI" or "angioplasty") and coronary artery bypass grafting ("CABG") as well as myocardial infarction ("MI" or heart attack). www.ischemix.com
Contact:
MacDougall Biomedical CommunicationsChris Erdman, 781-235-3060chris@macbiocom.com